Boehringer Ingelheim and Ablynx entered into an exclusive worldwide collaboration and license agreement worth almost US$265 M to discover and develop new therapies for Alzheimer’s disease using Ablynx’s Nanobodies® a novel class of antibody-derived therapeutic proteins.